Global Transcatheter Aortic Valve Replacement Market Forecast, 2022-2028

Description

List of Tables

Global Transcatheter Aortic Valve Replacement Market Size, Share & Trends Analysis By Approach (Transfemoral Approach, Transapical Approach, and Transaortic Approach), By Application (Aortic Valvular Heart Disease, Mitral Valvular Heart Disease, and Pulmonary Valvular Heart Disease), By End-User (Hospitals, Cardiac Centers, and Ambulatory Surgical Centers) Forecast, 2021-2027

The global transcatheter aortic valve replacement market is growing at a CAGR of around 11.4% during the forecast period (2021-2027). As per data published by Medicare and Medicaid Services, The growth of this market is due to the aortic stenosis patients, and the constantly increasing geriatric population. Thus, the increasing prevalence of aortic stenosis and improving treatment rates are expected to boost the growth of the market. In the US the large population plays a very major role in this market the required elderly population is likely to be doubled by 2050. People above the age of 75 years in the US are more likely to suffer from aortic stenosis thus reflects the huge amount of people suffering from this, due to high reimbursement rates, the demand for surgeries is increasing in the US, which will increase the market significantly. Moreover, technological advancements in replacement surgeries are also positively impacting the market. TAVR is a minimally invasive approach and is less invasive than conventional AVR. The use of sutureless valves in minimally invasive surgeries results in positive outcomes in terms of patient recovery, during the adverse effects.

The other factor that will drive this market is minimally invasive surgeries are suggested to patients, which in turn, the major key players are adopting different market strategies such as the US FDA approval. For instance, In April 2021, Abbott was received CE Mark from the US Food and Drug Administration for its next-generation TriClip. The clip-based therapy, known as TriClip G4, is a non-surgical heart valve repair option, precisely Transcatheter Tricuspid Valve Repair System. The device is designed for the treatment of leaky tricuspid valve, and treat tricuspid regurgitation (TR), that aid in the repair of the valve to each patient's unique anatomy. The device is available in Europe. Additionally, awareness programs are run by the government to aware people of the surgery are also drive the market growth. For instance, The valve for Life Initiative was launched by the European Association of Percutaneous Cardiovascular Interventions. This initiative was aimed at improving access to TAVR in Europe, raise awareness about valvular diseases, increase the knowledge of healthcare practitioners, reduce obstacles to therapy implementation, and improve patient outcomes.

Impact of COVID-19 on the Transcatheter Aortic Valve Replacement Market

COVID-19 is rising across the globe, the transcatheter aortic valve replacement market will not face any negative impact. As COVID-19 can be more severe to the patients having prior chronic diseases the manufacturers of this device are introducing new products which will help people indicated for both aortic regurgitation and stenosis, owning the increasing patient population that could be treated with the device. The manufactures of these devices started the commercialization of these devices and hence is specify that this market is not hit or faced any losses due to COVID-19 Pandemic.

Segmental Outlook

The market is segmented based on approach, application, and end-user. Based on the approach, the market is segmented into transfemoral approach, transapical approach, and transaortic approach. By application, the market is segmented into aortic valvular heart disease, mitral valvular heart disease, and pulmonary valvular heart disease. By end-user, the market is segmented into hospitals, cardiac centers, and ambulatory surgical centers.

Global Transcatheter Aortic Valve Replacement Market Share by End-User, 2020 (%)

Global Transcatheter Aortic Valve Replacement Market Share by End-User

The hospital segment is projected to hold a significant share in the global transcatheter aortic valve replacement market

Among end-user, the hospitals segment is projected to dominate the market due to the improved government guidelines for the management of vulvar diseases, favorable health reimbursement, and an increase in the number of procedures in hospitals to detects this type of disease. Special clinics grow slow in this sector owing to growing private practitioners and the requirements of the patients that cannot be fulfilled at the clinics. The hospital segments are also successful in this due to the hospital have the presence of skilled surgeons and the setting and availability of technology with advanced equipment and tools utilized in heart valve replacement procedures is increasing the number of people opting for transcatheter heart replacement.

Regional Outlooks

The global transcatheter aortic valve replacement market is analyzed based on the geographical regions that are contributing significantly towards the growth of the market. Based on the geography, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. The number of cases increases in Valvular disorders started increasing North America was the highest contributor of the market share. The government of North America has started the awareness regarding the benefits of TAVR over other surgical procedures this is some factor for the growth of the regional market. Moreover, reimbursement policies and awareness among the local people also play a vital role in the success of the regional market. around 1.5 million people suffer from aortic stenosis in the US, and according to the survey of their Institute 100,000+ replacement surgeries are performed every year in the country. The local presence of the key player and the increasing number of clinical studies have improved the market scenario.

Global Transcatheter Aortic Valve Replacement Market, by Region 2021-2027

Global Transcatheter Aortic Valve Replacement Market, by Region

Asia-Pacific will Have Considerable Growth in the Global Transcatheter Aortic Valve Replacement Market

Asia-Pacific is expected to witness significant growth opportunities for the market. The market is growing in Asia-Pacific due to developing economics such as India and China these countries have a population and the risk of heart diseases is prevailing more in this region. This Region also has a very high potential market due to the geriatric population and developing healthcare system, infrastructure, and services. All these factors improvise the growth of this market in this region, Also the government has started funding this type of program and started an awareness program for the benefit of the people.

Market Player Outlook

The major key players in this market are Boston Scientific Corp. Edwards Lifescience Corp. Medtronic, St. Jude Medical, Cryolife Science Livonova. These companies are developing various strategies such as mergers & acquisition, Extensive Clinical studies. For Instance, In December 2018, JenaValve Technology received approval from the US Food and Drug Administration for the treatment of patients with severe aortic stenosis and severe aortic regurgitation.

The Report Covers

Market value data analysis of 2020 and forecast to 2027.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global Transcatheter Aortic Valve Replacement market Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where in the market

Product Code: OMR2019530

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Impact of COVID-19 on the Global Transcatheter Aortic Valve Replacement Industry
Recovery Scenario of Global Transcatheter Aortic Valve Replacement Industry
1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segments
- 1.2.2. By Geography

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Recommendations
- 2.2.3. Conclusion

3. Competitive Landscape

3.1. Key Company Analysis
- 3.1.1. Overview
- 3.1.2. Financial Analysis
- 3.1.3. SWOT Analysis
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on Key Players

4. Market Determinants

4.1. Motivators
4.2. Restraints
4.3. Opportunities

5. Market Segmentation

5.1. Global Transcatheter Aortic Valve Replacement Market by Approach
- 5.1.1. Transfemoral Approach
- 5.1.2. Transapical Approach
- 5.1.3. Transaortic Approach
5.2. Global Transcatheter Aortic Valve Replacement Market by Application
- 5.2.1. Aortic Valvular Heart Disease
- 5.2.2. Mitral Valvular Heart Disease
- 5.2.3. Pulmonary Valvular Heart Disease
5.3. Global Transcatheter Aortic Valve Replacement Market by End-User
- 5.3.1. Hospitals
- 5.3.2. Cardiac Centers
- 5.3.3. Ambulatory Surgical Centers

6. Regional Analysis

6.1. North America
- 6.1.1. United States
- 6.1.2. Canada
6.2. Europe
- 6.2.1. UK
- 6.2.2. Germany
- 6.2.3. Italy
- 6.2.4. Spain
- 6.2.5. France
- 6.2.6. Rest of Europe
6.3. Asia-Pacific
- 6.3.1. China
- 6.3.2. India
- 6.3.3. Japan
- 6.3.4. South Korea
- 6.3.5. Rest of Asia-Pacific
6.4. Rest of the World

7. Company Profiles

7.1. 4C Medical Technologies
7.2. Abbott Laboratories
7.3. Boston Scientific Corp.
7.4. Braile Biomedica
7.5. Cardiosolutions, Inc.
7.6. Colibri Heart Valve LLC
7.7. Cryolife, Inc.
7.8. Edwards Lifesciences Corp.
7.9. HLT, Inc.
7.10. JC Medical, Inc.
7.11. Jenavalve Technology, Inc.
7.12. Lepu Medical Technology (Beijing) Co., Ltd
7.13. Livanova PLC
7.14. Medtronic, PLC
7.15. Meril Life Sciences Pvt. Ltd.
7.16. Micro Interventional Devices, Inc.
7.17. Neovasc Inc.
7.18. RUA Life Sciences Plc
7.19. TTK Healthcare Ltd.